Clinical outcomes among COVID-19 patients initiated on molnupiravir in Denmark - A national registry study
{{output}}
Background: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Dani... ...
